Radiotherapy for Diffuse Intrinsic Pontine Glioma: Insufficient but Indispensable

Area of Science:

• Pediatric Oncology
• Neuro-oncology
• Radiation Oncology

Background:

• Diffuse intrinsic pontine gliomas (DIPG) represent 10%-20% of pediatric central nervous system tumors.
• DIPG is the primary cause of mortality among children diagnosed with brain tumors, with over 90% succumbing within two years.
• Current treatment strategies, primarily radiotherapy, have not improved patient survival outcomes.

Purpose of the Study:

• To provide a comprehensive review of diffuse intrinsic pontine glioma (DIPG) management.
• To critically evaluate the role and limitations of radiotherapy in DIPG treatment.
• To highlight the urgent need for improved therapeutic approaches for DIPG.

Main Methods:

• Systematic literature review of clinical trials and management strategies for DIPG.
• Analysis of radiotherapy techniques, including hyperfractionated and hypofractionated approaches.
• Evaluation of the efficacy of radiosensitizers in conjunction with radiotherapy.

Main Results:

• Despite extensive research and clinical trials, radiotherapy has not demonstrated a significant survival benefit for DIPG patients.
• Investigated radiotherapy modifications and radiosensitizer additions have failed to improve the dismal prognosis.
• The overall survival for patients with DIPG remains approximately 11 months.

Conclusions:

• Radiotherapy remains the standard of care for DIPG but offers limited efficacy.
• Novel therapeutic strategies beyond current radiotherapy paradigms are crucial for improving DIPG outcomes.
• Further research into innovative treatments is essential to enhance survival rates for children with DIPG.